Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models-Reference-Cited by-同舟云学术

Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models

Published:2017-02-09 Issue:2 Volume:12 Page:e0171871
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Kenmogne Lucie Carolle,Roy Jenny,Maltais René,Rouleau Mélanie,Neveu Bertrand,Pouliot Frédéric,Poirier Donald

Funder

Canadian Institutes of Health Research

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference40 articles.

1. Canadian Cancer Statistics 2015,2015

2. Cancer Statistics, 2015;RL Siegel;Ca Cancer J Clin,2015

3. Blockade of testicular and adrenal androgens in prostate cancer treatment;F Labrie;Nat Rev Urol,2011

4. Compliance with hormonal treatment for prostate cancer;AV Kaisary;Br J Hosp Med,1995

5. Antiandrogens in tumor therapy;F Neumann;Clin Oncol,1982

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemical synthesis of fluorinated and iodinated 17β-HSD3 inhibitors and evaluation for imaging prostate cancer tumors and tissue biodistribution;Bioorganic Chemistry;2022-12

2. 16-Picolyl-androsterone derivative exhibits potent 17β-HSD3 inhibitory activity, improved metabolic stability and cytotoxic effect on various cancer cells: Synthesis, homology modeling and docking studies;The Journal of Steroid Biochemistry and Molecular Biology;2021-06

3. Combined MD and QM/MM Investigations of Hydride Reduction of 5α-Dihydrotestosterone Catalyzed by Human 3α-Hydroxysteroid Dehydrogenase Type 3: Importance of Noncovalent Interactions;The Journal of Physical Chemistry B;2021-05-06

4. The Curcumin Derivative, H10, Suppresses Hormone-Dependent Prostate Cancer by Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3;Frontiers in Pharmacology;2020-05-08

5. Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy;Journal of Urology;2020-05